Flag­ship takes a rare knock as cell re­place­ment start­up based on Bob Langer tech gets slapped with clin­i­cal hold

In the age of Mod­er­na, it’s rare to see sto­ried start­up ma­chine Flag­ship Pi­o­neer­ing take a loss — let alone for a team backed by re­search from Bob Langer’s lab. Nev­er­the­less, a great pedi­gree doesn’t mean there won’t be set­backs, a les­son an old­er Flag­ship brand is find­ing out the hard way.

The FDA has placed a clin­i­cal hold on Sig­ilon Ther­a­peu­tics’ non-vi­ral cell ther­a­py for he­mo­phil­ia A, dubbed SIG-001, af­ter a pa­tient in a Phase I/II tri­al re­port­ed a case of Fac­tor VI­II in­hi­bi­tion, the biotech said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER